Regeneron's VEGF Trap-Eye Caught In CATT's Claws
This article was originally published in The Pink Sheet Daily
Executive Summary
Regeneron's VEGF Trap-Eye is caught in the crosshairs in the comparative efficacy debate over Avastin and Lucentis.
You may also be interested in...
Allergan Licenses Molecular Partners' Anti-VEGF Protein For Ophthalmologic Indications
Privately held Swiss firm gets $45 million upfront in deal for Phase II candidate being studied in wet age-related macular degeneration and diabetic macular edema.
Allergan Licenses Molecular Partners' Anti-VEGF Protein For Ophthalmologic Indications
Privately held Swiss firm gets $45 million upfront in deal for Phase II candidate being studied in wet age-related macular degeneration and diabetic macular edema.
Lucentis And Avastin Stack Up In CATT, Forcing Genentech/Novartis To Play Defense
The efficacy of low-cost Avastin and pricier Lucentis for the treatment of wet-AMD are similar in the first head-to-head clinical trial to compare the two drugs, though Novartis and Genentech call out safety uncertainties.